Search Results 531-540 of 23340 for B cell lymphomas
The purpose of this study is to evaluate the effectiveness and safety of Nivolumab in previously treated (cohorts, A, B & C) or newly diagnosed (cohort D) ...
... B-cell Lymphoma (R/R DLBCL). Rochester, Minn. Study B9991011 is a multi-center, international, randomized, open label, 2 component (Phase 1b followed by ...
Cutaneous B-cell lymphoma · Cutaneous T-cell lymphoma · Diarrhea: Cancer-related causes and how to cope · Diffuse large B-cell lymphoma · Dr. Mark Truty ( ...
Safety/Efficacy of MEDI-551 in Combination With Immunomodulating Therapies in Subjects With Aggressive B-cell Lymphomas. Rochester, Minn. This is a Phase 1b ...
... B-cell lymphoma 2 (BCL2) inhibitor. A Novel Vaccine (EO2463) as Monotherapy ... Durvalumab is FDA approved for treatment in lung cancers including non-small cell ...
Giving rituximab together with romidepsin and lenalidomide may be a better treatment for B-cell non-Hodgkin lymphoma. Testing the Addition of an Anti-cancer ...
Follicular lymphoma (FL), marginal zone lymphoma (MZL), and mantle cell lymphoma (MCL) are distinct histologic types of B-cell NHL. Lenalidomide is an ...
Learn how this cancer differs from other lymphomas. Find out about risk ... cell lymphoma, Follicular lymphoma, B-cell lymphoma, T-cell lymphoma. Show ...
The subtypes we are studying are Diffuse Large B-Cell Lymphoma (DLBCL), Peripheral T-Cell Lymphoma (PTCL), Cutaneous T-Cell Lymphoma (CTCL), Primary Mediastinal ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Your donation powers the future of medicine and helps save lives.